Anticonvulsants

"Anticonvulsants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs used to prevent SEIZURES or reduce their severity.

Descriptor ID	D000927
MeSH Number(s)	D27.505.954.427.080
Concept/Terms	Anticonvulsants Anticonvulsants Anticonvulsive Agents Agents, Anticonvulsive Anticonvulsive Drugs Drugs, Anticonvulsive Anticonvulsant Drugs Drugs, Anticonvulsant Antiepileptic Agents Antiepileptic Agents Agents, Antiepileptic Antiepileptics Antiepileptic Drugs Drugs, Antiepileptic

Below are MeSH descriptors whose meaning is more general than "Anticonvulsants".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Anticonvulsants [D27.505.954.427.080]

Below are MeSH descriptors whose meaning is related to "Anticonvulsants".

Below are MeSH descriptors whose meaning is more specific than "Anticonvulsants".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Anticonvulsants" by people in this website by year, and whether "Anticonvulsants" was a major or minor topic of these publications.

Bar chart showing 129 publications over 27 distinct years, with a maximum of 10 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	2	2
1993	1	0	1
1997	2	2	4
1998	3	0	3
1999	4	1	5
2000	1	2	3
2001	3	2	5
2002	7	1	8
2003	4	3	7
2004	3	4	7
2005	1	3	4
2006	3	1	4
2007	2	4	6
2008	8	2	10
2009	4	2	6
2010	2	2	4
2011	5	2	7
2012	3	0	3
2013	8	1	9
2014	2	0	2
2015	3	3	6
2016	3	2	5
2017	1	1	2
2018	2	3	5
2019	3	1	4
2020	3	1	4
2021	1	2	3

Below are the most recent publications written about "Anticonvulsants" by people in Profiles.

French JA, Cole AJ, Faught E, Theodore WH, Vezzani A, Liow K, Halford JJ, Armstrong R, Szaflarski JP, Hubbard S, Patel J, Chen K, Feng W, Rizzo M, Elkins J, Knafler G, Parkerson KA. Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study. Neurology. 2021 11 02; 97(18):e1757-e1767.

View in: PubMed
Scheffer IE, Halford JJ, Miller I, Nabbout R, Sanchez-Carpintero R, Shiloh-Malawsky Y, Wong M, Zolnowska M, Checketts D, Dunayevich E, Devinsky O. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021 10; 62(10):2505-2517.

View in: PubMed
Patel AD, Mazurkiewicz-Beldzinska M, Chin RF, Gil-Nagel A, Gunning B, Halford JJ, Mitchell W, Scott Perry M, Thiele EA, Weinstock A, Dunayevich E, Checketts D, Devinsky O. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021 09; 62(9):2228-2239.

View in: PubMed
Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020 Aug; 142(2):91-107.

View in: PubMed
Sathe AG, Elm JJ, Cloyd JC, Chamberlain JM, Silbergleit R, Kapur J, Cock HR, Fountain NB, Shinnar S, Lowenstein DH, Conwit RA, Bleck TP, Coles LD. The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia. 2020 06; 61(6):e66-e70.

View in: PubMed
Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, Rosenfeld WE, Vossler DG, Wechsler R, Borchert L, Kamin M. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020 06; 61(6):1099-1108.

View in: PubMed
Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, Rogers A, Barsan W, Cloyd J, Lowenstein D, Bleck TP, Conwit R, Meinzer C, Cock H, Fountain NB, Underwood E, Connor JT, Silbergleit R. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 04 11; 395(10231):1217-1224.

View in: PubMed
Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N, Connor JT, Silbergleit R. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 11 28; 381(22):2103-2113.

View in: PubMed
Cock HR, Coles LD, Elm J, Silbergleit R, Chamberlain JM, Cloyd JC, Fountain N, Shinnar S, Lowenstein D, Conwit R, Bleck TP, Kapur J. Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy Behav. 2019 12; 101(Pt B):106296.

View in: PubMed
Wagner JL, Mueller M, Kellermann T, Griffin M, Smith G, Soliven M, Guilfoyle SM, Junger KF, Mucci G, Huszti H, Barrett L, Zupanc M, Modi AC. Vulnerabilities to antiepileptic drug (AED) side effects in youth with epilepsy. Epilepsy Behav. 2019 08; 97:22-28.

View in: PubMed

People

Explore

Similar Concepts

Top Journals